Mesoblast Ltd's stock price plummeted 5.17% during intraday trading on Friday, following the release of the company's financial results and guidance.

The biotech company reported a half-year loss attributable of $40.2 million alongside half-year total revenues of $51.3 million. Concurrently, Mesoblast provided its full-year fiscal 2026 net revenue guidance for its Ryoncil product, projecting it to range between $110 million and $120 million.

The significant half-year loss appears to have negatively impacted investor sentiment, leading to the sharp decline in the company's share price during the trading session.